NextenBio Subsidiary Rosvivo Files Patent Applications for miRNA Therapeutics Targeting COVID-19 Variants Including Omicron

[Asia Economy Reporter Jang Hyowon] RosVivo Therapeutics, a subsidiary of Nexton Bio, announced on the 15th that it has discovered an antiviral candidate substance called ‘anti-coronavirus miRNA’ that targets all seven COVID-19 variant viruses, including the Delta and Omicron variants, and is currently filing a patent with the University of Nevada, USA.

RosVivo stated that the anti-coronavirus miRNA discovered by Dr. No Seung-il’s team not only inhibits the replication of SARS-CoV-2 inside cells but also blocks the signaling of inflammatory cytokines (immune regulators) and their receptors.

The miRNA discovered by RosVivo was confirmed to target the RNA-dependent RNA Polymerase and Spike protein, which play important roles in the replication and infection of SARS-CoV-2 genes. It is known that administering this miRNA to COVID-19 patients could provide a new therapeutic approach capable of alleviating both SARS-CoV-2 infection and cytokine-induced inflammation.

A RosVivo official said, “It is significant in that it suggests the possibility of simultaneously suppressing infection by seven COVID-19 variant viruses including Omicron and the hypersensitive immune response causing severe symptoms by using miRNA-based new drug technology for the first time.” He added, “We will do our best to develop the anti-coronavirus miRNA into a COVID-19 treatment as soon as possible.”

This content was produced with the assistance of AI translation services.